文献速递骨软组织肉瘤与黑色素瘤

黑色素瘤中的丝裂原活化蛋白激酶通路第一部分——BRAF抑制的激活与原发性耐药机制

The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition.
PubMed 文献 · Eur J Cancer · 2017-02-03

综述阐述MAPK通路在正常细胞与BRAFV600突变细胞中的激活差异,指出BRAF/MEK抑制剂适用于携带BRAFV600突变的转移性黑色素瘤患者,但存在多种耐药机制。本文聚焦原发性或内在性耐药机制,即虽检出BRAF突变却对BRAF或MEK抑制剂无反应的情况。

要点

  • MAPK通路激活是多种细胞内过程的基本步骤,正常细胞中伴随上游负反馈调节。
  • BRAFV600突变细胞中负反馈缺失,导致MAPK通路持续激活和不受控增殖。
  • BRAF和/或MEK抑制剂适用于携带BRAFV600突变的转移性黑色素瘤患者。

核心结论

  • 在检出BRAF突变的情况下,部分患者对BRAF或MEK抑制剂治疗无反应,即存在原发性或内在性耐药机制。

研究设计与样本

  • 综述,聚焦于BRAF和MEK抑制的原发性或内在性耐药机制。

主要发现

  • 正常细胞中MAPK通路激活导致细胞生长和分化,并伴随生理性上游负反馈以防止通路持续激活。
  • 携带BRAFV600突变的细胞中,导致MAPK通路激活的过程不同,生理性负反馈不存在,导致MAPK通路永久激活,最终可导致不受控增殖。

临床怎么用

  • BRAF和/或MEK抑制剂适用于携带BRAFV600突变的转移性黑色素瘤患者。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mitogen-activated protein kinase (MAPK) pathway has an important role in normal cells and can be activated under physiological conditions. MAPK pathway activation is a fundamental step in several intracellular processes requiring a sequential phosphorylation of the different pathway components. In normal cells, when MAPK pathway activation occurs, it leads to cell growth and differentiation. In order to prevent persistent MAPK pathway activation, physiological upstream negative feedback also takes place. In cells harbouring BRAFV600 mutations, the process leading to MAPK pathway activation is different, and the negative physiological feedback does not exist thus leading to permanent MAPK pathway activation, which ultimately can lead to uncontrolled proliferation. Targeted therapy with rapidly accelerated fibrosarcoma - B (BRAF) and/or mitogen-activated extracellular signal-regulated kinase kinase (MEK) inhibitors is indicated in patients with metastatic melanoma harboring BRAFV600 mutations. However, several different resistance mechanisms to this therapy were identified. In this review, we focus on primary or intrinsic resistance mechanisms to BRAF and MEK inhibition. In this setting, although a BRAF mutation is identified, there is no response to treatment with either BRAF or MEK inhibitor.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Amaral T, Sinnberg T, Meier F, et al. The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition. Eur J Cancer. 2017. PMID: 28169047. doi:10.1016/j.ejca.2016.12.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。